India Glycols gets NCLT nod for demerger, clears final hurdle
The National Company Law Tribunal approved the separation of bio-pharma and spirits businesses into Ennature Bio Pharma Ltd. and IGL Spirits Ltd., enabling independent listings.
— 3 earlier stories on India Glycols Ltd. →What's new
- NCLT Allahabad sanctioned India Glycols' demerger scheme on July 17, 2026.
- Bio-pharma arm becomes Ennature Bio Pharma Ltd.; spirits & biofuel arm becomes IGL Spirits Ltd.
- Approval is the final regulatory milestone for the restructuring.
Why this matters
The demerger removes the major legal overhang that clouded India Glycols' sum-of-parts value. With two pure-play entities set to list independently, the market can now assign distinct valuations to the bio-pharma and spirits businesses. That could produce a premium over the current diversified conglomerate structure.
What we're watching
- Timeline for filing the NCLT order and listing of Ennature Bio Pharma and IGL Spirits.
- Whether the spirits arm's new COO from Pernod Ricard accelerates profitability improvement.
- Progress toward India Glycols' stated target of debt-free status by FY29.
The full read
India Glycols has crossed the final regulatory milestone for its demerger. The NCLT Allahabad sanctioned the scheme on July 17, 2026, splitting the company into three listed entities: Ennature Bio Pharma Ltd. for bio-pharma, IGL Spirits Ltd. for spirits and biofuel, and India Glycols itself retaining chemicals. The approval removes the major legal overhang that kept sum-of-parts valuations in check. The ₹6,404 cr market cap now faces a potential re-rating as pure-play peers trade at higher multiples. The timing is good: India Glycols had already appointed an ex-Pernod Ricard COO for the spirits arm, prepaid ₹804 cr of debt in Q4, and targets debt-free status by FY29. The next milestones, listing dates and shareholder entitlement ratios, will determine how quickly the value materialises.
Questions answered
- Which businesses are being demerged from India Glycols?
- The bio-pharma undertaking goes into Ennature Bio Pharma Ltd., and the spirits and biofuel undertaking goes into IGL Spirits Ltd. The remaining company will hold the chemicals and other businesses.
- When will the new entities start trading independently?
- The exact listing date depends on filing of the NCLT order and subsequent approvals. The company says it will submit the order once uploaded on the NCLT website.
- How will existing shareholders be affected?
- Shareholders of India Glycols will receive shares in both demerged entities in a predetermined ratio, as per the scheme sanctioned by the NCLT. The record date has not been announced yet.
- Does the demerger help India Glycols' debt reduction plans?
- Yes. India Glycols had already prepaid ₹804 cr in Q4 FY26 and targets debt-free status by FY29. Separating the businesses allows each entity to manage its own capital structure, potentially speeding up debt reduction.
- What is the profit profile of India Glycols?
- In the latest quarter (Mar 2026), India Glycols posted sales of ₹2,360 cr and net profit of ₹74 cr. The demerger is expected to help the market better assess the profitability of each segment.
- Was the NCLT approval anticipated?
- Yes, the market largely expected approval given the scheme's progression, but the definitive order removes any residual legal uncertainty and is a definite positive catalyst.
India Glycols Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on INDIAGLYCO →- 17 Jul 2026 · 6:17 PM IST India Glycols gets NCLT nod for demerger, clears final hurdle
- 15d ago India Glycols' spirits arm brings in ex-Pernod Ricard exec as COO
- 56d ago India Glycols targets debt-free status by FY29
- 56d ago India Glycols sues New India Assurance for ₹79.76 cr over 2020 plant damage